ClinicalTrials.gg
RecruitingNCT06488807Updated May 14, 2025

Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment

An interventional study of Olfactory Enrichment and Sham in Perioperative Neurocognitive Disorder, sponsored by Shanghai 10th People's Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Shanghai 10th People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
686
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Neurocognitive Disorders with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Neurocognitive Disorders · China.

Planned enrollment
6th of 15
686 · median 264
Started
2025
with 1 other
No phase
9 of 22
6 open now
Primary completion
2027-12
later than 9 of 13 live
Registered
15th of 22
by date

Among the 22 studies in Neurocognitive Disorders with a site in China, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 15th registered.

Neurocognitive Disorders

275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.

Browse Neurocognitive Disorders studies →

Open to participants now

13 of the 22 studies in Neurocognitive Disorders with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Neurocognitive Disorders studies recruiting now, 38 (62%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neurocognitive Disorders with a site in China, or all of them as a file.
02

Study summary

Perioperative neurocognitive disorder (PND) is one of the most common postoperative complications among elderly patients. However, the mechanism and targeted intervention of PND remains unclear. Our previous clinical studies demonstrated the association between olfactory impairment and PND. Moreover, our translational studies showed that anesthesia/surgery induced olfactory impairment and caused cognitive impairment in mice and olfactory enrichment could prevent the anesthesia/surgery-induced cognitive impairment. However, there was no clinical investigation to determine whether olfactory enrichment can mitigate PND in elderly patients. Therefore, we propose determining whether olfactory enrichment can prevent and/or treat PND in elderly patients.

Read the detailed description

The study will be a double-blinded, randomized controlled trial. Participants (65 years old or older) undergoing scheduled orthopaedic surgery (≥2 hours, under general anesthesia) will be randomized to either olfactory enrichment group or sham group. Participants in olfactory enrichment group will receive olfactory enrichment with a dispenser twice sessions per day on preoperative day 1-3 and postoperative day 1-3 (30 min per session, 4 odors for each session) while participants in sham group will be equipped with the same pattern except that water will be used in the dispenser. Participants will be assessed twice daily by a research assistant blinded to allocation. The primary outcome will be the incidence of postoperative delirium measured by the Confusion Assessment Method on postoperative days 1, 2 and 3. The secondary outcomes will be the severity of postoperative delirium, cognitive function, plasma Tau-PT217 level, and olfactory function.

03

Conditions studied

  • Perioperative Neurocognitive Disorder

Keywords

  • Perioperative Neurocognitive Disorder
  • Odor Enrichment
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥65 years old.
  2. Having a scheduled surgery (≥2 hours, general anesthesia) (e.g., total hip replacement, toal knee replacement, open reduction and internal fixation of hip and lumbar spine).
  3. Being able to complete neuropsychological tests, 3D-CAM and CAM-S.
  4. Chinese Mandarin as their native language.
  5. Edmonton frailty scale (EFS) score ≥ 6.

Exclusion criteria

Exclusion Criteria:

  1. Having delirium, assessed by 3D-CAM, before surgery.
  2. Having a brain tumour, stroke or mental disorders (eg, major depressive disorder or dementia).
  3. Participating in other clinical studies at the time of screening.
  4. Unwillingness to comply with the protocol or procedures.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
686 participants (estimated)

Study arms

  • Experimental
    Olfactory Enrichment Group

    All participants enrolled in the olfactory enrichment group will receive twice sessions per day with an interval of at least 6 hours on preoperative day 1 and postoperative day 1-3. Each session will last 30 minutes. Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, tangerine, green tea, cloves and eucalyptus). When pushing a button, 4 odors will be released in turn and participants will sniff each odor (approximately 4 ml odorized air) for approximately 30 seconds by a nasal catheter. Considering of the adaption of odors, 4 odors will be used in the morning session and another 4 odors will be used in the afternoon session.

    Other: Olfactory Enrichment

  • Sham comparator
    Sham Group

    The sham group will receive sham olfactory enrichment sessions, which is designed with the same pattern (twice a day, 30 min for each session, on preoperative day 1 and on postoperative day 1-3. However, the containers provided to the sham group will be odorless. The odor containers and labels will appear identical to those used in the olfactory enrichment group.

    Other: Sham

Interventions

  • OtherOlfactory Enrichment

    Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.

  • OtherSham

    The containers provided to the sham group will be odorless. The odor containers and labels will appear identical to those used in the olfactory enrichment group.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    The presence of postoperative delirium will be defined according to 3D-CAM, which includes four entries: acute onset and fluctuating course, inattention, disorganized thinking and altered level of consciousness. To diagnose delirium, both the first and second criteria have to be present plus the third and/or fourth criteria. Every participant will be assessed twice daily after anesthesia/surgery from postoperative day 1 to postoperative day 3, with the first assessment between 8:00 and 10:00. The second assessment will be between 15:00 and 17:00.

    Time frame: at baseline and postoperative day 1 to 3

Secondary outcomes

  1. Incidence of delayed neurocognitive recovery and postoperative neurocognitive disorder

    Participants' cognitive function will be assessed at baseline, on postoperative day 21, and at postoperative month 6 using a battery of neuropsychological tests, including the Montreal Cognitive Assessment (MoCA), Hopkins Verbal Learning Test Retention (HVLTRet), Hopkins Verbal Learning Test Total Recall (HVLTTR), Brief Visuospatial Memory Test Total Recall (BVMTTR), Brief Visuospatial Memory Test Delayed Recall (BVMTDR), Benton Judgment of Line Orientation (JLO), Digit Span Test (DST), Verbal Fluency Test (VFT) and Trail Making Test (TMT). Cognitive Change Index will be calculated by subtracting baseline scores from postoperative scores in each of the neuropsychological tests. Delayed neurocognitive recovery or postoperative neurocognitive disorder will be defined as by a decrease by one or more standard deviations in at least two of the neuropsychological tests from the baseline to 21 days or 6 months after anesthesia/surgery.

    Time frame: at baseline, on 21 days and 6 months after anesthesia/surgery

Other outcomes

  1. Severity of delirium

    Severity of delirium will be assessed by the CAM-S. CAM-S includes 10 items: acute onset or symptom fluctuation, inattention, disorganized thinking, altered level of consciousness, disorientation, memory impairment, perceptual disturbances, psychomotor agitation, psychomotor retardation and sleep-wake cycle disturbance. Each item is scored as absent (0), mild (1) or marked (2), except acute onset or fluctuation, which is scored as absent (0) or present (1). The sum of CAM-S ranges from 0 (none) to 19 (most severe). The Delirium Symptom Interview (DSI) Daily will be used to determine CAM-S grades. The incidence of postoperative delirium will also be referred to the records by nurses on duty.

    Time frame: at baseline and postoperative day 1 to 3

  2. Severity of delayed neurocognitive recovery and postoperative neurocognitive disorder

    Severity of delayed neurocognitive recovery and postoperative neurocognitive disorder will be assessed by battery of neuropsychological tests at baseline, on postoperative day 21, and at postoperative month 6. The scores of neuropsychological tests indicate cognitive functions which can reflect the severity of delayed neurocognitive recovery and postoperative neurocognitive disorder.

    Time frame: at baseline, on 21 days and 6 months after anesthesia/surgery

  3. Activities of Daily Living

    Activities of daily living will be assessed using the Chinese version of the ADL scale at baseline, and on postoperative day 21 days and 6 months after anesthesia/surgery, including a Physical Self-Maintenance Scale and an Instrumental Activities of daily living at baseline (before the surgery) and follow-ups. There are a total of 14 items in the Activities of daily living. For each item, scoring is determined by a 4-point coding system: 1 = 'can do it myself,' 2 = 'have some difficulty but can still do it by myself,' 3 = 'need help to do it,' and 4 = 'cannot do it at all.' A higher score therefore indicates greater impairment in activities of daily living. Specifically, a total activities of daily living score of 14 signifies no impairment, scores of 15-21 indicate mild impairment, and scores of ≥22 reflect severe impairment. Participants with Activities of daily living scores of more than 22 points will be considered to have substantive impairment in Activities of daily living.

    Time frame: at baseline, on 21 days and 6 months after anesthesia/surgery

  4. Plasma Tau-PT217 Concentrations

    Five milliliters of blood will be collected from participants immediately before and after anesthesia/surgery, 3 days, 21 days and 6 months postoperatively. Blood samples will be centrifuged at 500 g for 10 minutes, and the plasma supernatant will be collected. The plasma will be collected in EDTA tubes, immediately placed on ice, and then stored in a -80°C freezer until analysis. The samples will be thawed at the time of measurement. Tau-PT217 concentrations in plasma will be measured using Nanoneedle technology.

    Time frame: immediately before and after anesthesia/surgery, 3 days, 21 days and 6 months postoperatively

  5. Olfactory Function Determination

    Olfactory function will be assessed at baseline and on postoperative day 3, 21 and 6 months after anesthesia/surgery. The assessment will include odor threshold (scored from 1 to 20) and odor identification (scored from 0 to 16) tests, using pen-like odor dispensing devices to evaluate nasal chemosensory performance.

    Time frame: at baseline and on postoperative day 3, 21 and 6 months after anesthesia/surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 80 non-industry interventional studies with no phase under Neurocognitive Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 32 months is above that.

Counting every sponsor, half of 83 studies reached it within 27 months; a quarter within 15 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2024
First posted
Jul 5, 2024
StartActual
Apr 7, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06488807
Collaborators
National Natural Science Foundation of China
Responsible party
Yuan Shen, MD, PhD (Director, Shanghai 10th People's Hospital) — Principal investigator
First posted
Jul 5, 2024
Start date
Apr 7, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 14, 2025

Study contacts

Yuan Shen
Contact
dr.yuanshen@foxmail.com
+8618602169932
Yuan Shen
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion